GlaxoSmithKline Pharmaceuticals discloses SEBI Regulation 30(5) compliance regarding materiality determination authority.
Board authorizes four key officers to determine event materiality for stock exchange disclosures.
Authorized personnel include Managing Director, CFO, Company Secretary, and Head of Legal.
Disclosure made to BSE and NSE on April 21, 2026 as regulatory requirement.